Conclusion High reticulocyte count is associated with increased risk of death in patients awaiting LT. Remodelling UKELD to include high reticulocyte count improved accuracy of predicting death on the LT waiting list.

Competing interests None declared.

PTU-064 PRE-LIVER TRANSPLANT BIOPSY IN HEPATOCELLULAR CARCINOMA: A POTENTIAL EXCLUSION CRITERION FOR TRANSPLANTATION?

doi:10.1136/gutjnl-2012-302514c.64

¹R Young,* ¹M Aldiwani, ¹A Hakeem, ¹A Nair, ²J Wyatt, ¹G Toogood, ¹P Lodge, ³R Jones, ¹R Prasad. ¹Department of Hepatobiliary and Transplant Surgery, St James's University Hospital, Leeds, UK; ²Department of Histopathology, St James's University Hospital, Leeds, UK; ³Department of Hepatology, St James's University Hospital, Leeds, UK

Introduction In cirrhotic patients with hepatocellular carcinoma (HCC) pre-liver transplant (LT) staging biopsy of the largest tumour is undertaken in some centres. Proponents advocate that poor differentiation confers such poor prognostic significance that it can be used as an exclusion criterion for LT, resigning patients to palliative treatments. We do not carry out staging biopsies and sought to interrogate its potential use and impact on our practice in the context of ever increasing demands for organs.

Methods 65 consecutive patients undergoing orthotopic LT for radiologically diagnosed HCC at St James's University Hospital between 2006 and 2011 were identified for analysis from a prospectively maintained database. All patients had cirrhosis and incidental tumours were excluded. Diagnosis was in accordance to published guidelines and various clinic-pathological parameters were recorded. MRI findings were correlated with explant histological examination. Median follow-up was 24 months. Student t test, Mann–Whitney U test or related samples Wilcoxon Signed Rank tests were used where appropriate. The Kaplan–Meier method was used to determine survival with Log-Rank and Cox stepwise regression for survival comparisons. $p < 0.05$ was considered to be statistically significant.

Results 3 year survival was 81% with the only independent predictor microvascular invasion ($p = 0.019$). In 5 (7.7%) patients there was no HCC in the explant. A discrepancy between the definition of the largest lesion on pre-LT radiology and the largest explant tumour occurred in 5 (7.7%) cases. Tumours were classified as well, moderately or poorly differentiated in 39 (30.2%), 66 (51.2%) and 24 (18.6%) cases. In patients with multifocal HCC, 9 (34.6%) had tumours of differing grades. In two (7.7%) patients the largest tumour was well differentiated while smaller tumours in the explant were poorly differentiated. In one patient the largest lesion was benign with other smaller invasive carcinomas confirmed histologically.

Conclusion There is a need to optimise LT selection strategies for HCC. Microvascular invasion was the only independent predictor of outcome and the challenge of predicting it pre-operatively remains. Crucially, the largest lesion was not always representative of overall tumour burden or biological aggression and its potential use to exclude patients from curative treatment is questionable.

Competing interests None declared.

PTU-065 LONG TERM OUTCOMES OF LIVER TRANSPLANTATION FOR WILSON'S DISEASE: A SINGLE CENTRE EXPERIENCE

doi:10.1136/gutjnl-2012-302514c.65

H Al-Hilou, S Hebbat,* B K Gunson, L C Claridge, W-K Syn, A P Holt. *Liver unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK*

Introduction Wilson's disease is an autosomal recessive disorder of copper metabolism which may manifest as acute or chronic liver

disease and/or neuropsychiatric disorders. Orthotopic liver transplantation (OLT) is life saving when performed for acute liver failure or end-stage liver disease but there are conflicting reports on the effects of OLT on neuropsychiatric symptoms. Furthermore, a recent report from an Italian group has highlighted poor outcomes following OLT in those with neuropsychiatric symptoms.

Aim To evaluate the indications and outcomes of OLT for patients with Wilson's disease and in particular to assess the effects of OLT on neuropsychiatric symptoms, and whether these disorders are associated with poor outcomes.

Methods Data were acquired by retrospective analysis of case notes and databases.

Results 21 adults with Wilson's disease have been transplanted in Birmingham between 1987 and 2011. 53.3 % (11/21) were performed for acute liver failure and 42.8% (9/21) for decompensated cirrhosis. One patient was transplanted due to hepatocellular carcinoma. Median age was 19.5 at diagnosis and 25 at time of OLT. 10 patients had neuropsychiatric symptoms prior to OLT (Parkinsonism in three patients, anxiety in two patients, epilepsy, OCD, depression, ataxia and migraine). These symptoms resolved in 4/10 post-OLT. However, four patients developed new onset neuropsychiatric symptoms within 2 weeks of OLT; two patients had seizures, one developed psychosis and another became euphoric. Kayser–Fleisher (KF) rings are purportedly associated with neuropsychiatric disorders; in our cohort 61.9% (13/21) of patients had KF rings and 11/13 of these had neuropsychiatric symptoms. Four patients had significant post-operative complications comprising four haemorrhagic episodes and two biliary leaks. Actuarial survival rates were 95% at both 1 and 5 years. One patient died within 3 months of OLT and three patients died >10 years post OLT. 3/4 deaths were due to multi-organ failure secondary to sepsis. Graft survival was 90% at 1 year and 81% at 5 years. Five patients have required re-grafting; three due to chronic rejection and two due to hepatic artery thrombosis. There were no appreciable differences in long term outcomes between those with and without pre-existing neuropsychiatric symptoms; 2/4 deaths and 2/5 re-grafts were in those with neuropsychiatric manifestations.

Conclusion Outcomes of OLT for Wilson's disease are comparable to transplantation for other diagnoses. Neuropsychiatric symptoms improved in <50% of patients post-OLT and may also occur for the first time following OLT. At our centre pre-existing neuropsychiatric symptoms were not associated with poor outcomes.

Competing interests None declared.

PTU-066 AN "ALCOHOL CONTRACT" HAS NOT REDUCED RATES OF POST-TRANSPLANT DRINKING FOLLOWING TRANSPLANTATION FOR ALCOHOLIC LIVER DISEASE

doi:10.1136/gutjnl-2012-302514c.66

S Kendrick,* A Elsharkawy, S Latimer, M Hudson, S Masson. *Liver Unit, Newcastle upon Tyne Hospitals Foundation Trust, Newcastle upon Tyne, UK*

Introduction Reports of patients returning to drinking after orthotopic liver transplantation (OLT) for alcoholic liver disease (ALD) remain a source of unease for professionals and the public. Recidivism rates of 10%–16% are reported with a low rate of alcohol-related graft loss.^{1 2} In 2005, the UK Transplant liver advisory group recommended an "alcohol contract" in which ALD patients listed for OLT confirmed in writing their commitment to abstinence.³ The purpose of our study was to measure the rates and consequences of post-OLT alcohol intake in a UK transplant program and assess the effect of the "alcohol contract" on rates of post-transplant drinking.

Methods Prospectively collected data were reviewed for 100 randomly selected patients transplanted for ALD—32 patients

transplanted since the “alcohol contract” was implemented (February 2007) and 68 patients transplanted before.

Results Overall (n=100; 62 male, median age 54), 37 patients reported some alcohol intake post-OLT. The proportion of patients returning to any alcohol was 35.3% before the “alcohol contract” and 40.6% after (NS; p=0.66). For heavy drinking (>21 units [168 g ethanol]/week) this was 16.2% and 15.6%, respectively (NS; p=1.0). Four patients underwent OLT despite pre-transplant liver histology consistent with active ALD. After OLT, one of these returned to heavy drinking and another denied drinking but had a positive blood alcohol. At explant, 10 patients had features of active ALD: six of these returned to drinking post-OLT. Blood alcohol was measured in only 24 of 63 patients reporting abstinence. Two had positive tests; one of these subsequently disclosed heavy drinking. During follow-up, 23 patients died. Most deaths (87%) occurred in those (63%) who did not return to drinking. Only one death in 673 patient-years of follow-up could be directly attributed to alcohol intake.

Conclusion Post-OLT recidivism is higher in our cohort than other published series but the impact of drinking on post-transplant survival remained low. The introduction of an “alcohol contract” may have value in improving public perception of transplantation in ALD patients but is insufficient to alter rates of recidivism. Random blood alcohol testing is inadequate to detect post-transplant drinking. More robust abstinence support and better assessment measures might improve outcomes.

Abstract PTU-066 Figure 1

Competing interests None declared.

REFERENCES

1. Tomé, et al. *J Hepatol* 2002;**36**:793–8.
2. Wells, et al. *Liver Transplantation* 2007;**13**:1728–35.
3. Bathgate, et al. *Lancet* 2006;**367**:2045–6.

PTU-067

OUT-PATIENT ASSESSMENT FOR LIVER TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE

doi:10.1136/gutjnl-2012-302514c.67

¹T R Lim,* ¹M J Armstrong, ¹D D Houlihan, ¹K Wong, ²C Cook, ¹A Turner, ¹M Perrin, ¹J Cantrill, ¹P Ashcroft, ¹D Hughes, ¹C Weijers, ¹A Holt. ¹Hepatology, University Hospitals Birmingham, Birmingham, UK; ²Finance, University Hospitals Birmingham, Birmingham, UK

Introduction Assessment for orthotopic liver transplantation (LT) traditionally requires admission to hospital. In 2010, the liver unit at the University Hospital Birmingham (UHB) launched the first UK-based out-patient assessment programme (OPA). This study aims to describe our experience, with specific focus on feasibility, efficacy, cost-effectiveness and patient satisfaction.

Methods Patients undergoing elective LT assessment were retrospectively analysed between June 2010 and April 2011. Data

collected included patient demographics/clinical features, LT assessment parameters, duration to listing/LT and reasons for LT refusal. An extensive cost evaluation was performed on both in- and out-patient LT assessment, including clinical tests, staffing and hospital facilities utilised. Patient satisfaction questionnaires were collected prospectively from April 2011 to November 2011.

Results 179 patients underwent LT assessment. 87/94 successfully completed OPA, with seven converted to in-patient LT assessment (IPA) due to pre-existing co-morbidity including refractory ascites and hepatic encephalopathy. All patients referred for OPA were triaged 2 weeks prior to the assessment to ensure suitability. 92 patients successfully underwent IPA. 66/87 OPAs were subsequently listed for LT (median duration from OPA to listing 3 days [0–306], of which 37/66 received a cadaveric graft. The reasons for OPAs not listed include: too early for LT (50.0%), contraindication to LT (42.9%) and patient refusal (7.1%). 53/92 IPAs were listed, mean duration 4 days [1–39], of which 34/53 were transplanted. Reasons for IPAs not listed: contraindication to LT (48.2%), too early for LT (44.4%) and patient refusal (7.4%). A single IPA costs on average £14441 as compared to £11494 for an OPA. Overall satisfaction (mean score 9.6/10; 10=very satisfied, 1=very dissatisfied) and convenience (7.9/10) for patients undergoing OPA were high.

Conclusion We describe for first time that OPA is feasible, efficient and cost-effective. With increasing demand on hospital beds in the UK National Health Service, such a programme has the potential to reduce the burden on LT in-patient services.

Abstract PTU-067 Table 1 Patient demographics and clinical features

	OPA (n=87)	IPA (n=92)
Mean age (±SD)	52.3 (±1.3)	55.0 (±0.9)
Male sex (%)	58.6	54.3
Aetiology		
Viral	6	11
Alcohol	6	21
HCC	26	12
Metabolic	9	20
Autoimmune/biliary	30	13
Other	10	15
UKELD median [range]	51 [43–66]	53 [43–67]
Liver co-morbidities		
Encephalopathy	23	40
Refractory ascites	0	7
Variceal bleeding	14	8
Other co-morbidities		
Hypertension	10	3
Diabetes	11	10
Renal impairment	1	4

Competing interests None declared.

Hepatobiliary I

PTU-068

BILIARY MATRIX METALLOPROTEINASE 9 LEVELS ARE INDEPENDENT OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN IN PATIENTS WITH MALIGNANT BILIARY OBSTRUCTION

doi:10.1136/gutjnl-2012-302514c.68

¹A Latif, ¹A Zabron,* ¹V Horneffer-Van der Sluis, ¹C Wadsworth, ²D Westaby, ²P Vlavianos, ¹S Taylor-Robinson, ³R Edwards, ¹S Khan. ¹Department of Gastroenterology/Hepatology, Imperial College London, London, UK; ²Gastroenterology Unit,